[{"NetIncomeLoss_1_Q1_USD":-79679000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_0_Q1_USD":5012000.0,"CommitmentsAndContingencies_0_Q1_USD":null,"DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_0_Q1_USD":0.0,"InterestPaidNet_1_Q1_USD":14385000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q1_USD":17000.0,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":113697000.0,"AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1_Q1_USD":5593000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q1_USD":1000.0,"AssetsCurrent_0_Q1_USD":293071000.0,"DueFromRelatedPartiesCurrent_0_Q1_USD":42359000.0,"LongTermDebt_0_Q1_USD":614070000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_1_Q1_USD":36000.0,"IncreaseDecreaseInPrepaidExpensesOther_1_Q1_USD":-322000.0,"SellingGeneralAndAdministrativeExpense_1_Q1_USD":30550000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q1_shares":15159000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q1_USD":3000.0,"ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_1_Q1_USD":115500000.0,"CommonStockSharesIssued_0_Q1_shares":65218000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q1_USD":157271000.0,"Assets_0_Q1_USD":375108000.0,"OtherNoncashIncomeExpense_1_Q1_USD":-46000.0,"ShareBasedCompensation_1_Q1_USD":15832000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q1_shares":64493000.0,"PreferredStockSharesOutstanding_0_Q1_shares":0.0,"DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_0_Q1_USD":1000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q1_shares":64493000.0,"IncreaseDecreaseInAccruedLiabilities_1_Q1_USD":-17299000.0,"OtherNonoperatingIncomeExpense_1_Q1_USD":-234000.0,"IncomeTaxExpenseBenefit_1_Q1_USD":227000.0,"CommonStockValue_0_Q1_USD":1000.0,"InterestPayableCurrent_0_Q1_USD":5804000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":-11288000.0,"OtherDepreciationAndAmortization_1_Q1_USD":1539000.0,"ConvertibleLongTermNotesPayable_0_Q1_USD":227230000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_0_Q1_USD":1000.0,"OtherPrepaidExpenseCurrent_0_Q1_USD":10037000.0,"ComprehensiveIncomeNetOfTax_1_Q1_USD":-79709000.0,"IncreaseDecreaseInAccountsPayable_1_Q1_USD":-1073000.0,"OtherAssetsNoncurrent_0_Q1_USD":2304000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":114011000.0,"OperatingLeaseLiabilityNoncurrent_0_Q1_USD":57026000.0,"IncreaseDecreaseInOtherNoncurrentLiabilities_1_Q1_USD":224000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q1_USD":-30000.0,"EquityMethodInvestments_0_Q1_USD":19439000.0,"RestrictedCash_0_Q1_USD":833000.0,"OperatingLeaseRightOfUseAsset_0_Q1_USD":42517000.0,"PreferredStockParOrStatedValuePerShare_0_Q1_USD":0.0,"RepaymentsOfNotesPayable_1_Q1_USD":5698000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q1_USD":20000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q1_USD":-79452000.0,"DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries_0_Q1_USD":0.0,"PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1_Q1_USD":5593000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q1_USD":15832000.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-69865000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":64723000.0,"PaymentsToAcquireProductiveAssets_1_Q1_USD":1767000.0,"LiabilitiesCurrent_0_Q1_USD":86492000.0,"IncomeLossFromEquityMethodInvestments_1_Q1_USD":16547000.0,"AccountsPayableCurrent_0_Q1_USD":6834000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q1_USD":114844000.0,"ProceedsFromStockOptionsExercised_1_Q1_USD":3000.0,"OtherAccruedLiabilitiesCurrent_0_Q1_USD":1833000.0,"FinanceLeaseRightOfUseAssetAmortization_1_Q1_USD":743000.0,"IncreaseDecreaseInOtherOperatingAssets_1_Q1_USD":-65000.0,"AdditionalPaidInCapital_0_Q1_USD":1233060000.0,"DebtSecuritiesAvailableForSaleUnrealizedLossPosition_0_Q1_USD":5012000.0,"PreferredStockSharesIssued_0_Q1_shares":0.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":16944000.0,"InterestExpense_1_Q1_USD":11873000.0,"RestrictedCashNoncurrent_0_Q1_USD":833000.0,"CommonStockSharesOutstanding_0_Q1_shares":65218000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1_Q1_USD":32544000.0,"CommonStockParOrStatedValuePerShare_0_Q1_USD":0.0,"FairValueAssetsLevel1ToLevel2TransfersAmount_0_Q1_USD":0.0,"CommonStockSharesAuthorized_0_Q1_shares":200000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q1_USD":14257000.0,"OperatingIncomeLoss_1_Q1_USD":-83892000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q1_USD":95957000.0,"IncreaseDecreaseInInterestPayableNet_1_Q1_USD":1830000.0,"ContractWithCustomerLiabilityCurrent_0_Q1_USD":7661000.0,"PreferredStockValue_0_Q1_USD":null,"LiabilitiesAndStockholdersEquity_0_Q1_USD":375108000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q1_USD":15624000.0,"PreferredStockSharesAuthorized_0_Q1_shares":230000.0,"AllocatedShareBasedCompensationExpense_1_Q1_USD":15832000.0,"OperatingLeaseLiabilityCurrent_0_Q1_USD":1220000.0,"OperatingExpenses_1_Q1_USD":98149000.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":-1.24,"OtherLiabilitiesNoncurrent_0_Q1_USD":2058000.0,"StockholdersEquity_0_Q1_USD":-373218000.0,"ContractWithCustomerLiabilityNoncurrent_0_Q1_USD":339000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q1_USD":157252000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-1606296000.0,"ResearchAndDevelopmentExpense_1_Q1_USD":67599000.0,"IncreaseDecreaseInContractWithCustomerLiability_1_Q1_USD":-3871000.0,"Ticker":"TBPH","CIK":"1583107","name":"THERAVANCE BIOPHARMA, INC.","OfficialName":"Theravance Biopharma Inc. Ordinary Shares","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"688048421.0","Country":"Cayman Islands","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210506"}]